NTRK1 and early-onset autosomal dominant Alzheimer disease: An increasing number of studies support the notion that NGF and TrkA are promising targets for new therapeutics for the treatment of Alzheimer's disease (Allen, Watson, & Dawbarn, 2011; Cattaneo & Calissano, 2012; Iulita & Cuello, 2015; Xu, Wang, & Jin, 2016).